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The glycation-induced functional change of immunoglobulins is of particular interest. The
glycation levels of IgG in 10 healthy subjects and 20 diabetic patients with different degrees of
metabolic control were studied by matrix-assisted laser desorption/ionization (MALDI) mass
spectrometry. It reveals the number of glucose molecules that have condensed on the protein,
which range from 1 to 5 for healthy subjects, from 5 to 9 for well controlled diabetic patients,
and from 10 to 25 for poorly controlled ones. The identification of the most favored glycation
sites has been obtained by MALDI analysis of standard and in vitro glycated IgG and plasma
protein fraction of a healthy subject after digestion with papain, releasing Fab and Fc
fragments of the molecule. Both experiments, as well as molecular modeling of the whole
protein, confirm that the most of glucose molecules have condensed on the Fab fragment of
IgG, suggesting that the immune deficiency observed in diabetic patients may be explained at
the molecular level by a more effective glycation of the Fab fragment, thus inhibiting the
process of molecular recognition between antibody and antigen. (J Am Soc Mass Spectrom
2000, 11, 153–159) © 2000 American Society for Mass Spectrometry
Nonenzymatic protein glyco-oxidation [1] is animportant chemical process which occurs nat-urally in biological fluids and tissues. It takes
place through the reaction of glucose with protein
amino groups, mainly the terminal ones and the
e-amino groups of lysines belonging to the protein
chain [2]. The yield of these reactions depends to a
considerable extent on reactant concentration and, even
if they take place in healthy subjects, they become
particularly important in the presence of high glucose
concentrations, as in diabetes. In this context, nonenzy-
matic protein glyco-oxidation has been invoked as a
rationale for the tissue modifications observed in long-
term diabetic complications [3], as well as in some
ageing-related processes [4]. Glyco-oxidized proteins
may react with others, thus leading to protein crosslink-
ing, which reflects on different tissue morphology [5].
In principle, glycated proteins exhibit a functionality
which is different from that of unglycated ones. This
has been suggested for human serum albumin, hemo-
globin, and a series of intracellular enzyme proteins [6].
However, the change in functionality of glycated pro-
teins is still a widely debated subject, mainly because of
the few, scattered data available on the number and
position of glycated protein sites and, in particular,
their relationship with biochemical and clinical data. In
this frame, the glycation-induced functional changes of
immunoglobulins is of particular interest. Investiga-
tions have been devoted to verifying whether immuno-
globulin glycation, occurring at higher levels in diabetic
patients, could contribute to their increased susceptibil-
ity to infections [7, 8]. Some of these studies show that
incubation of IgG with high glucose concentrations
leads to reduced complement-fixing (Fc) activity [9, 10].
A similar experimental approach on IgM [11, 12]
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showed that glycation mainly takes place on its frag-
ment antigen binding (Fab)-like fragments, affecting its
agglutination properties. However, other studies yield
disparate results [13–17].
Mass spectrometry (MS) has recently been employed
in the field of nonenzymatic protein glycation, provid-
ing important results, and being able to operate on
intact proteins without any sample manipulation. In
particular, matrix-assisted laser desorption/ionization
(MALDI) [18] and electrospray (ES) [19] are highly
effective, as shown by a series of investigations on
differently glycated proteins, in both in vitro and in
vivo, using the advantages typical of the two methods
[20–26]. Looking at these results, we are interested in
the application of the MALDI/MS technique in an
investigation of the glycation level of IgG from healthy
and diabetic subjects [26]. In order to investigate IgG
glycation sites, further investigations were carried out
by in vitro reaction of glucose with commercially avail-
able IgG and with plasma protein fraction of a healthy
subject. The reaction products have been enzymatically
digested by papain and the digested fractions were
analyzed by MALDI/MS. In parallel with these exper-
imental investigations, molecular modeling of the
whole IgG protein has been employed to obtain infor-
mation on the most accessible lysine residues present in
the chain, assumed on the basis of literature [2], as
targets for possible glycation processes. We emphasize
that the main aim of this paper is to determine the
extent of glycation in Fab and Fc fragments, and not to
identify the glycation sites on the IgG substructures.
Materials and Methods
Subjects
10 poorly controlled, non-insulin-dependent diabetic
patients [mean age 6 standard deviation (SD): 67 6 3
years, mean disease duration 13 6 9 years, mean fast-
ing plasma glucose 21.5 6 5 mmol/L, mean HbA1c
11.4 6 2%], 10 well controlled, non-insulin-dependent
diabetic patients (mean age 61 6 12 years, mean disease
duration 12 6 8 years, mean fasting plasma glucose
7.8 6 1 mmol/L, mean HbA1c 7.4 6 0.8%), and 10
normal controls (mean age 59 6 9 years, mean fasting
plasma glucose 5 6 0.4 mmol/L, mean HbA1c 5.3 6
0.6%) were studied. On the day of the study, fasting
plasma glucose and glycated haemoglobin (HbA1c)
were evaluated in all subjects, and plasma samples
were taken for MALDI measurements. All subjects gave
their informed consent to the study, which was per-
formed in accordance with the Helsinki declaration
[27].
Preparation of Plasma Protein Fractions
0.5 mL of plasma were passed through an AMICON
(Amicon, Beverly, MA) membrane (cut-off 10,000 Da) in
order to eliminate free glucose and salts, and then
centrifuged at 3000 rev/min for 30 min in a Varifuge 3.2
RS (Heraeus, Osterode, Germany). Supernatants were
discarded, and samples, after deionized water had been
added to obtain the initial volume, were further centri-
fuged at 3000 rev/min for 30 min. After supernatants
were removed, the samples were evaporated to dryness
under nitrogen and then lyophilized.
In Vitro Glycation of Plasma Protein Fraction
The plasma protein fraction of a healthy subject (4 mg)
was incubated with D-glucose (Sigma, St. Louis, MO) at
concentration 1 M in 4 mL Na-phosphate buffer (0.05
M) at pH 7.5. The obtained solution was added to 0.5%
of toluene to avoid bacterial contamination and then
incubated at 37 °C under sterile conditions for 28 days.
The sample was then dialyzed in order to eliminate free
glucose.
In Vitro Glycation of Standard IgG
IgG (4 mg) (Sigma, St. Louis, MO) was incubated with
D-glucose (Sigma) at concentration 0.5 M in 4 mL
Na-phosphate buffer (0.05 M) at pH 7.5. The obtained
solution was added to 0.5% of toluene to avoid bacterial
contamination and then incubated at 37 °C under sterile
conditions for 28 days. The sample was then dialyzed in
order to eliminate free glucose.
Digestion of Glycated and Unglycated Standard
IgG and Plasma Protein Fraction
Glycated and unglycated standard IgG as well as gly-
cated and unglycated plasma proteins from a healthy
subject were digested with papain [7] in 0.075 mol/L
Na-phosphate, 0.075 mol/L NaCl buffer, pH 7, contain-
ing 0.01 mol/L cysteine. Digestion at 37 °C of proteins
at a concentration of 10 mg/mL was performed for 4 h
using an enzyme to protein ratio 1/100 (w/w).
Methods
Plasma glucose was evaluated by a glucose-oxidase
enzymatic method [28]. HbA1c was determined by a
HPLC procedure [29].
MALDI measurements were performed on a RE-
FLEX time-of-flight mass spectrometer (Bruker-Franzen
Analytik, Bremen, Germany) equipped with a SCOUT
ion source, operating in the positive linear mode. Ions
formed by a pulsed UV laser beam (nitrogen laser, l 5
337 nm) were accelerated at 30 keV. The UV laser light
(energy about 50 mJ) was focused on to the sample
using a focal diameter varying from 100 to 300 mm. In
this case, laser power attenuation of 50% was used. The
matrix was sinapinic acid, dissolved in acetonitrile/
water (50:50 v:v) at a concentration of about 5 3 1022
mol/L. For MALDI measurements, samples were dis-
solved in 0.1% trifluoroacetic acid aqueous solution at a
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concentration of about 6 mg/mL and diluted five times
with the same solvent. 5 mL of the final sample solution
were added to 5 mL of the matrix solution and about 1
mL of this mixture was deposited on the stainless steel
multiprobe and allowed to dry before introduction into
the mass spectrometer. Mass spectra were obtained and
averaged over 10 shots; three independent MALDI
measurements were made for each sample to evaluate
reproducibility. Mass accuracy ranging from 0.01% to
0.1% was always obtained. The experimental molecular
weight of pure IgG (148,267 6 37 Da), purchased from
Sigma (St. Louis, MO) was determined and checked
daily by averaging the values obtained in various
MALDI experiments, using bovine serum albumin
(BSA) (Sigma, St. Louis, MO) (66,431 Da) and BSA-
dimer (132,859 Da) as external calibrants.
Computer-Molecular Modeling
The entire IgG1 immunoglobulin, the human myeloma
protein Kol, was built by computer-molecular modeling
starting from the Protein Brookhaven Database files
2ig2.pdb and 1fc2.pdb (Brookhaven National Labora-
tory, Upton, NY). The files contain the respective atomic
coordinates for fragments Fab (VH, CH1, VL, and CL)
and Fc (CH2, CH3) of IgG1. From the X-ray structure of
Fc we eliminated the polysaccharide residues and a
fragment of protein C with which the heavy chain of
IgG1 was complexed. After dimerization of Fab and Fc,
according to the symmetry operations described in the
database, both parts were manually docked, evaluating
van der Waalls nonbonded energy, to obtain the classi-
cal Y shape of IgG.
Only fragments Pro-Ala-Pro-Glu-Leu-Leu-Gly-Gly
of the N-terminal chain of Fc and Ser-Pro-Gly of the
C-terminal were missing. The former were arbitrarily
added to join aminoacids Cys230 and Pro238 and
energy minimized, keeping the Fab and Fc fragments
constrained in their crystallographic atomic coordi-
nates. The C-terminal fragments were not considered in
this work. The SAS of all aminoacids were determined
on this structural model and the values for the lysine
residues present were extracted.
All modeling was carried out using the SYBYL and
BIOPOLYMER modules of TRIPOS commercial soft-
ware (1699 S. Hanley Road, St. Louis, MO). The SAS of
the aminoacids making up the structure of IgG1 were
calculated using the Xsight module of MSI software
(9685 Scranton Road, San Diego, CA).
Results and Discussion
The implication of glycation processes in the function-
ality changes of immunoglobulins has been recently
discussed by Dolhofer et al., showing that complement
fixation and Fc function are impaired after in vitro
incubation of human IgG with high glucose concentra-
tions [16]. However, in another study [30], the same
authors stated that IgG from diabetic patients showed
no immunoreactivity with antiserum from rabbits im-
munized with proteins modified by advanced glycation
end products. The interpretation of these results was
that modifications unlike those caused by AGEs (oxida-
tion and/or glyco-oxidation reactions) must occur, to
explain the impaired Fc function in IgG of diabetic
patients. However, it was emphasized that in vivo
glycated IgG does not have the same epitopes gener-
ated in in vitro conditions.
Looking at the valuable results obtained by
MALDI/MS in the evaluation of glycation levels of
HSA [23] and hemoglobin [24, 25], we thought to apply
the same methodology in the case of IgG glycation, in
order to establish either the possibly different glycation
levels in healthy and diabetic subjects, or if glycation
takes place preferentially on Fab or Fc fragments of IgG.
The MALDI spectrum of a standard sample of IgG is
shown in Figure 1a. It consists of two main peaks at m/z
148,286 and 74,478, corresponding to singly and doubly
Figure 1. MALDI mass spectra of (a) standard IgG and (b) IgG
contained in a protein plasma fraction of a poorly controlled
diabetic subject.
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protonated IgG molecules, respectively. The former
peak is clearly detectable in the MALDI spectra of
plasma protein fractions, although at higher m/z values
as may be seen in Figure 1b.
The glycation level of proteins of interest can be
easily determined by MALDI by comparing their mo-
lecular weights with those of standard samples. The
mass difference (DM) between glycated and standard
proteins can be assigned to the glucose molecules
condensed on the reactive sites of the protein. As the
condensation of a glucose molecule leads to a mass
increase of 162 Da, the number of glucose residues on
the proteins can easily be calculated.
Analyses of various sets of IgG from healthy, well
controlled, and poorly controlled diabetic subjects
showed a general increase in molecular weight (Table
1), fully confirming what previously observed [26].
Figure 2 shows the histograms of mass differences
between subject IgG and standard IgG mass values.
These values are in the range 211–4270 Da, correspond-
ing to the condensation on IgG of different numbers of
glucose molecules, ranging from 1 to 25.
However, two points must be taken into account: (1)
the reported mass value must be considered to be
related to the most abundant species present in the
glycated IgG set; (2) oxidation processes may occur on
the glucose molecules condensed on the proteins. The
above numbers of glucose molecules (from 1 to 25) were
calculated by considering that the simple condensation
of one glucose molecule on the protein leads to a mass
increase of 162 Da. If further oxidative modifications
and dehydration of glucose, leading to a lowering of the
molecular weight, are taken into account, it follows that
the above data are indicative of the minimum number
of glucose molecules condensing on the protein.
The mean DM value (6SD) obtained for healthy
subjects is 532 6 324, whereas it becomes 1095 6 333
and 2822 6 1157 for well and poorly controlled diabetic
patients, respectively. These mass values correspond to
different numbers of glucose molecules condensing on
IgG, in the ranges 1–5 for healthy subjects, 5–9 for well
controlled diabetic patients, and 10–25 for poorly con-
Figure 3. MALDI mass spectrum of glycated standard IgG.
Table 1. Mass values (Da) obtained for IgG (at peak apex) from healthy subjects (a), well controlled diabetic patients (b), and poorly
controlled diabetic patients (c)
a b c
Subjects
Mass
value Subjects
Mass
value Subjects
Mass
value
1 148,577 11 149,540 21 151,990
2 148,880 12 149,654 22 149,113
3 149,412 13 149,375 23 152,556
4 148,826 14 149,851 24 150,971
5 148,497 15 149,405 25 150,277
6 148,673 16 149,072 26 152,154
7 148,607 17 148,798 27 150,927
8 149,379 18 149,620 28 150,648
9 148,664 19 149,381 29 149,973
10 148,662 20 149,112 30 152,472
Figure 2. Histograms of DM values of IgG obtained for 10
healthy subjects (a), 10 well controlled (b), and 10 poorly con-
trolled diabetic patients (c). DM values are simply calculated as
differences between IgG molecular weight obtained for the vari-
ous subjects and that corresponding to standard IgG (148,286 Da).
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trolled ones. Worth noting is the fact that the DM
standard deviation (SD) is of the same order of magni-
tude in the case of healthy and well controlled diabetic
subjects, but increases in the case of poorly controlled
diabetics. This gives a clear idea of the power of MALDI
in characterizing metabolic control among various pa-
tients within the same group, giving physicians a more
specific diagnostic tool.
However, MALDI data on the intact protein fraction
alone allow determination of the total number of glu-
cose molecules condensed on IgG, but they are ineffec-
tive in identifying the glycation sites, responsible for the
possibly different activity of Fab and/or Fc compo-
nents.
The usual approach employed to identify the prefer-
ential localization of these sites in the IgG molecules
requires, at least, sample treatment consisting of: IgG
separation — enzymatic or chemical digestion of pro-
teins — identification by a suitably specific analytical
method of glycation extent in digested fractions. To
obtain such information, incubation in pseudo physio-
logical conditions of standard IgG with 0.5 M glucose
for 28 days was performed. The spectrum of the protein
after incubation is reported in Figure 3. As may be seen
comparing it with Figure 1a, a mass increase of 4910 Da
is observed, corresponding to the addition of 30 glucose
molecules on the native protein. By enzymatic digestion
of native and glycated IgG, the MALDI mass spectra
reported in Figure 4 have been obtained. In the former
case, two peaks at m/z 47,601 and 52,797 are detected,
corresponding to protonated Fab and Fc fragments,
respectively. In the case of digested glycated IgG, these
two peaks are shifted at m/z 49,338 and 54,560. Taking
into account that the molar ratio between Fab and Fc
fragments is 2:1, results in 20 glucose molecules con-
densed on the Fab portion of IgG, whereas 10 are
condensed on the Fc portion of the protein.
A further investigation was carried out by incubation
in pseudophysiological conditions of the plasma pro-
tein fraction of a healthy subject with 1 M glucose for 28
days. The highest glucose concentration (1 M) was
Figure 4. MALDI mass spectra of unglycated (a) and glycated (b)
standard IgG after digestion with papain.
Figure 5. MALDI mass spectra of plasma protein fraction of a
healthy subject before (a) and after (b) incubation with glucose.
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employed for the presence of other reactive proteins,
competing against IgG for glycation. The spectra of
proteins before and after incubation are reported in
Figure 5; in the former case the ion at m/z 149,155 is due
to IgG, whereas the ion at m/z 67,024 is due to HSA. For
the incubated sample a mass increase of 4166 Da for IgG
is observed, corresponding to the addition of 26 glucose
molecules on the native protein.
After digestion with papain, Fab and Fc fragments
are released; in the case of unglycated sample they lead
to the peaks at m/z 47,503 and 53,285, respectively (see
Figure 6a), whereas in the case of glycated sample (see
Figure 6b) they show a mass increase of 1458 and 1236,
respectively. These data indicate that 18 glucose mole-
cules are condensed on the Fab fragment chain,
whereas only 8 are condensed on the Fc fragment.
To gain further evidence of the above described
results, computer-molecular modeling of the entire IgG
was used. The low pka a-amino group of proteins, due
to its higher nucleophilicity, are the most reactive sites
for the initial formation of Schiff base adducts. In the
reactivity scale against glucose the a-amino groups are
followed by the e-amino groups of lysine belonging to
the protein chain [2]. For such reasons we assumed that
the most of glucose molecules condensed on IgG orig-
inate by the interaction between lysine e-amino group
and glucose. Figure 7 shows the a-carbon trace of IgG
and the 82 lysine residues present in the structure. The
latter are randomly distributed on the Fab and Fc
fragments of the molecule of the antibody. Theoreti-
cally, all the e-amino groups of these lysine residues are
targets for the nonenzymatic addition of glucose. Ac-
cording to the molecular weight data obtained by
MALDI analysis of various samples, not all the lysine
residues are prone to react with glucose.
It was assumed that the lysine residues most reactive
towards the sugar were those whose structures were
more greatly exposed, because of their higher probabil-
ity of interacting with glucose. On these bases we
calculated the solvent accessible surfaces (SAS, Å2) for
each lysine and, as shown in Figure 8, we color coded
the most exposed lysine residues. Their distribution on
the IgG molecule confirms that Fab fragments are more
prone to attack by glucose, particularly in their light
and heavy variable regions (VL and CL) (top right in
Figure 8). VL and CL are important structural moieties
Figure 6. MALDI mass spectra of papain digested plasma pro-
tein fraction of a healthy subject before (a) and after (b) incubation
with glucose.
Figure 7. a-carbon trace of IgG1 and 82 lysine residues present in
the structure, which result in random distribution of Fab and Fc
fragments on an antibody molecule.
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for the process of molecular recognition between anti-
body and antigen.
In conclusion, MALDI mass spectrometry on the Fab
and Fc fragments and molecular modeling on the whole
IgG molecule have led to relevant common results,
suggesting that the immune deficiency observed in
diabetic patients may be explained, at a molecular level,
by a more effective glycation of the Fab fragment of
IgG, thus inhibiting the process of molecular recogni-
tion between antibody and antigen.
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Figure 8. The most solvent-exposed lysine residues color coded
according to their range of solvent accessible surfaces (SAS, Å2).
Only half the molecule of the IgG1 antibody is reported because of
its molecular symmetry. Yellow lysine residues, with the highest
SAS value, are the first to be glycated, and then the red, green, and
violet ones. Their distribution on the molecule of IgG shows that
the Fab fragment is extensively attacked by glucose.
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